Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,269.45 -8.06 (-0.15%) Dow
38,520.24 -166.08 (-0.43%) Nasdaq
16,768.99 +33.98 (+0.20%) Bitcoin USD
69,067.77 +979.23 (+1.44%) CMC Crypto 200
1,488.77 +20.83 (+1.42%)
GSK Jan 2026 40.000 put
- Yahoo Finance Video
GSK stock sinks after court allows Zantac lawsuits to proceed
Shares of Britain-based pharmaceutical company GSK plc (GSK) — formerly known as GlaxoSmithKline — are sliding in pre-market trading and into Monday's session open following a court ruling that has approved more than 70,000 lawsuits to go forward over heartburn medication Zantac's alleged links to cancer. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
- Business Wire
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer
- Evening Standard
FTSE 100 Live 3 June: GSK shares tumble, Monzo turns first profit
GSK shares are today’s major focus after the drugs giant’s defence against Zantac claims suffered a setback in a Delaware court. The FTSE 100 index is trading higher after Friday’s late rally by Wall Street markets was further boosted by this week’s prospect of an ECB interest rate cut. Other companies in the spotlight today include FTSE 250-listed Hollywood Bowl, having posted an 11% rise in half-year profits.
